CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
University of California, Santa Cruz |
Dr. Bin Chen |
SEED Grant |
In vitro differentiation of hESCs into corticospinal motor neurons |
$465,624 |
Human BioMolecular Research Institute |
Dr. John R Cashman |
SEED Grant |
Discovering Potent Molecules with Human ESCs to Treat Heart Disease |
$688,274 |
Buck Institute for Age Research |
Dr. Dale E. Bredesen |
SEED Grant |
Programmed Cell Death Pathways Activated in Embryonic Stem Cells |
$728,950 |
University of California, Los Angeles |
Dr. Douglas L. Black |
Basic Biology II |
Programs of alternative splicing regulation by polypyrimidine tract binding protein |
$1,344,562 |
University of California, San Diego |
Dong-Er Zhang |
Basic Biology II |
RUNX1 in maintenance, expansion, and differentiation of therapeutic pluripotent stem cells |
$1,371,540 |
University of California, Irvine |
Professor Marian L Waterman |
Basic Biology II |
TCF-3: A Wnt Pathway Effector and Nanog Regulator in Pluripotent Stem Cell Self-Renewal |
$1,259,879 |
iPierian, Inc. |
Dr. Irene Griswold-Prenner |
Basic Biology II |
Cellular Reprogramming: Dissecting the Molecular Mechanism and Enhancing Efficiency |
$1,458,000 |
Palo Alto Veterans Institute for Research |
Dr. Tony Wyss-Coray |
Basic Biology II |
Systemic Protein Factors as Modulators of the Aging Neurogenic Niche |
$1,159,806 |
Stanford University |
Professor Garry P Nolan |
Basic Biology II |
Kinase signaling analysis of iPS cell reprogramming and differentiation |
$1,343,100 |
University of California, Los Angeles |
Dr. Benhur Lee |
Basic Biology II |
The EphrinB2/EphB4 axis in regulating hESC pluripotency and differentiation |
$1,371,936 |
University of California, Davis |
Dr. Eric A Kurzrock |
Basic Biology II |
Differentiation of Human Embryonic Stem Cells into Urothelium |
$849,037 |
University of California, Los Angeles |
Dr. Yong Kim |
Basic Biology II |
Novel Mechanism in Self-Renewal/Differentiation of Human Embryonic Stem Cells |
$1,259,371 |
University of California, San Diego |
Dr. Kun-Liang Guan |
Basic Biology II |
The function of YAP in human embryonic stem cells |
$1,245,693 |
Stanford University |
Dr. Aaron J Hsueh |
Basic Biology II |
Maturation of Human Oocytes for SCNT and Embryonic Stem Cell Derivation |
$1,309,018 |
University of California, San Francisco |
Dr. John L Rubenstein |
Basic Biology II |
MGE Enhancers to Select for Interneuron Precursors Produced from Human ES Cells |
$1,387,800 |
Sanford Burnham Prebys Medical Discovery Institute |
Dr. Huei-sheng Vincent Chen |
Basic Biology II |
Endothelial cells and ion channel maturation of human stem cell-derived cardiomyocytes |
$1,587,610 |
University of California, Irvine |
Dr. Aileen J Anderson |
Basic Biology II |
Role of the microenvironment in human iPS and NSC fate and tumorigenesis |
$1,256,194 |
Stanford University |
Dr. Steven Edward Artandi |
Basic Biology II |
Self-renewal and senescence in iPS cells derived from patients with a stem cell disease |
$931,285 |
Salk Institute for Biological Studies |
Ronald Mark Evans |
Basic Biology II |
Molecular Characterization and Functional Exploration of Nuclear Receptors in hiPSCs |
$1,712,880 |
Calimmune, Inc. |
Geoff Symonds |
Disease Team Research I |
GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE |
$8,278,722 |
Stanford University |
Dr. Gary Steinberg |
Disease Team Research I |
Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke |
$17,244,851 |
University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Disease Team Research I |
Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis |
$5,694,308 |
University of California, Los Angeles |
Dr. Donald B. Kohn PhD |
Disease Team Research I |
Stem Cell Gene Therapy for Sickle Cell Disease |
$8,833,695 |
University of California, Los Angeles |
Dr. Irvin SY Chen |
Disease Team Research I |
HPSC based therapy for HIV disease using RNAi to CCR5. |
$9,905,604 |
ViaCyte, Inc. |
Allan Robins |
Disease Team Research I |
Cell Therapy for Diabetes |
$0 |
Cedars-Sinai Medical Center |
Eduardo Marbán |
Disease Team Research I |
Autologous cardiac-derived cells for advanced ischemic cardiomyopathy |
$5,560,232 |
University of California, San Francisco |
Dr. Mitchel S Berger |
Disease Team Research I |
Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) |
$6,214,914 |
City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Disease Team Research I |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
Stanford University |
Dr. Alfred T Lane |
Disease Team Research I |
iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,039,208 |
Stanford University |
Professor Irving L Weissman MD |
Disease Team Research I |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
University of California, Los Angeles |
Dr. Dennis J Slamon |
Disease Team Research I |
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Disease Team Research I |
ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
University of Southern California |
Dr. Mark S Humayun |
Disease Team Research I |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$18,904,916 |
University of California, San Diego |
Dr. Dennis A Carson |
Disease Team Research I |
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
University of California, San Diego |
Gene Wei-Ming Yeo |
Basic Biology I |
RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency |
$1,308,901 |
University of California, San Diego |
Karl H. Willert |
Basic Biology I |
WNT signaling and the control of cell fate decisions in human pluripotent stem cells. |
$1,329,298 |
University of California, Davis |
Dr. Min Zhao |
Basic Biology I |
Directing migration of human stem cells with electric fields |
$816,228 |
University of California, Los Angeles |
Dr. Michael A. Teitell |
Basic Biology I |
Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
University of Southern California |
Dr. Martin Pera |
Basic Biology I |
The stem cell microenvironment in the maintenance of pluripotency and reprogramming |
$1,325,723 |
Stanford University |
Dr. Julien Sage |
Basic Biology I |
The retinoblastoma (RB) gene family in cellular reprogramming |
$1,357,085 |
Stanford University |
Dr. Susan K McConnell |
Basic Biology I |
Identification and characterization of human ES-derived DA neuronal subtypes |
$1,404,853 |
University of California, Los Angeles |
Dr. Bennett G Novitch Ph.D. |
Basic Biology I |
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,228,278 |
University of California, Los Angeles |
Dr. Robb Maclellan Dr. |
Basic Biology I |
Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$917,667 |
University of Southern California |
Dr. Wange Lu |
Basic Biology I |
Defining the molecular mechanisms of somatic cell reprogramming |
$1,365,580 |
Stanford University |
Dr. Helen M Blau |
Basic Biology I |
Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,408,332 |
University of California, Los Angeles |
Dr. Luisa Iruela-Arispe |
Basic Biology I |
Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
University of California, San Francisco |
Mark C. Walters M.D. |
Conference – The 2019 Alpha Stem Cell Clinic Annual Symposium |
2019 Alpha Stem Cell Clinic Symposium – Mending Stem Cells: The Past, Present & Future Regenerative Medicine |
$60,000 |
University of California, Los Angeles |
John S. Adams |
Conference – The 2018 Alpha Stem Cell Clinic Annual Symposium |
Delivery of Stem Cell Therapeutics to Patients |
$60,000 |
International Alliance for Biological Standardization |
Dr. Anthony Lubiniecki |
Conference – Manage a Symposium on Pluripotent Stem Cell Manufacturing |
Basis of Standardization for Cell Therapies |
$100,000 |
University of California, Irvine |
Daniela A. Bota |
Alpha Stem Cell Clinics Network Expansion |
A hub and spoke community model to equitably deliver regenerative medicine therapies to diverse populations across four California counties |
$8,000,000 |